RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

• Status: Enrolling by invitation
• Trial end date: 2025-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess whether TNFa antibody use before lung transplant can prevent kidney injury after lung transplant.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Treatments: Etanercept

Criteria

Inclusion Criteria:

• Planning to undergo transplantation of the lung at Northwestern Memorial Hospital.

• Willing and able to read, understand, and be capable of giving informed consent.

Exclusion Criteria:

• Previous or current use of TNFa antibody.

• Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating.